TY - JOUR
T1 - The Effect of Genetic HLA Matching on Liver Transplantation Outcome
T2 - A Systematic Review and Meta-Analysis
AU - Kok, Gautam
AU - Ilcken, Eveline F
AU - Houwen, Roderick H J
AU - Lindemans, Caroline A
AU - Nieuwenhuis, Edward E S
AU - Spierings, Eric
AU - Fuchs, Sabine A
N1 - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2023/9
Y1 - 2023/9
N2 - OBJECTIVE: We aim to investigate the effects of genetically based HLA matching on patient and graft survival, and acute and chronic rejection after liver transplantation.BACKGROUND: Liver transplantation is a common treatment for patients with end-stage liver disease. In contrast to most other solid organ transplantations, there is no conclusive evidence supporting human leukocyte antigen (HLA) matching for liver transplantations. With emerging alternatives such as transplantation of bankable (stem) cells, HLA matching becomes feasible, which may decrease the need for immunosuppressive therapy and improve transplantation outcomes.METHODS: We systematically searched the PubMed, Embase, and Cochrane databases and performed a meta-analysis investigating the effect of genetic HLA matching on liver transplantation outcomes (acute/chronic rejection, graft failure, and mortality).RESULTS: We included 14 studies with 2682 patients. HLA-C mismatching significantly increased the risk of acute rejection (full mismatching: risk ratio = 1.90, 95% confidence interval = 1.08 to 3.33,
P = 0.03; partial mismatching: risk ratio = 1.33, 95% confidence interval = 1.07 to 1.66,
P = 0.01). We did not discern any significant effect of HLA mismatching per locus on acute rejection for HLA-A, -B, -DR, and -DQ, nor on chronic rejection, graft failure, or mortality for HLA-DR, and -DQ.
CONCLUSIONS: We found evidence that genetic HLA-C matching reduces the risk of acute rejection after liver transplantation while matching for other loci does not reduce the risk of acute rejection, chronic rejection, graft failure, or mortality.
AB - OBJECTIVE: We aim to investigate the effects of genetically based HLA matching on patient and graft survival, and acute and chronic rejection after liver transplantation.BACKGROUND: Liver transplantation is a common treatment for patients with end-stage liver disease. In contrast to most other solid organ transplantations, there is no conclusive evidence supporting human leukocyte antigen (HLA) matching for liver transplantations. With emerging alternatives such as transplantation of bankable (stem) cells, HLA matching becomes feasible, which may decrease the need for immunosuppressive therapy and improve transplantation outcomes.METHODS: We systematically searched the PubMed, Embase, and Cochrane databases and performed a meta-analysis investigating the effect of genetic HLA matching on liver transplantation outcomes (acute/chronic rejection, graft failure, and mortality).RESULTS: We included 14 studies with 2682 patients. HLA-C mismatching significantly increased the risk of acute rejection (full mismatching: risk ratio = 1.90, 95% confidence interval = 1.08 to 3.33,
P = 0.03; partial mismatching: risk ratio = 1.33, 95% confidence interval = 1.07 to 1.66,
P = 0.01). We did not discern any significant effect of HLA mismatching per locus on acute rejection for HLA-A, -B, -DR, and -DQ, nor on chronic rejection, graft failure, or mortality for HLA-DR, and -DQ.
CONCLUSIONS: We found evidence that genetic HLA-C matching reduces the risk of acute rejection after liver transplantation while matching for other loci does not reduce the risk of acute rejection, chronic rejection, graft failure, or mortality.
KW - acute rejection
KW - HLA
KW - HLA matching
KW - human leukocyte antigen
KW - liver transplantation
KW - transplantation outcomes
U2 - 10.1097/AS9.0000000000000334
DO - 10.1097/AS9.0000000000000334
M3 - Article
C2 - 37746594
SN - 2691-3593
VL - 4
SP - 1
EP - 7
JO - Annals of surgery open : perspectives of surgical history, education, and clinical approaches
JF - Annals of surgery open : perspectives of surgical history, education, and clinical approaches
IS - 3
M1 - e334
ER -